Comparisons: Continuing Treatment vs. Last Measure Before Dropout
| Group | Endpoint | |||||
|---|---|---|---|---|---|---|
| Continued Treatment | Before Dropout | ANOVA | ||||
| N | Mean±Std. Error | N | Mean±Std. Error | |||
| Craving for opiates | ||||||
| 2 weeks | PI+OP | 64 | 3.2±0.36 | 38 | 3.1±0.46 | Main group effect F2, 300=1.374; P=0.255 Main endpoint effect F1, 300=0.144; P=0.704 group*endpoint interaction F2, 300=2.305; P=0.102 |
| PI+ON | 79 | 2.9±0.32 | 23 | 4.5±0.60 | ||
| NI+OP | 97 | 3.1±0.29 | 5 | 2.2±1.28 | ||
| 4 weeks | PI+OP | 50 | 1.4±0.31 | 14 | 1.9±0.63 | Main group effect F2, 234=0.483; P=0.617 Main endpoint effect F1, 234=0.016; P=0.899 group*endpoint interaction F2, 234=0.385; P=0.680 |
| PI+ON | 65 | 1.0±0.27 | 14 | 1.6±0.70 | ||
| NI+OP | 96 | 1.4±0.22 | 1 | 0.0±2.10 | ||
| 8 weeks | PI+OP | 30 | 0.5±0.26 | 2 | 0.3±0.63 | Main group effect F2, 155=3.014; P=0.052 Main endpoint effect F1, 155=0.109; P=0.741 group*endpoint interaction F2, 155=0.944; P=0.391 |
| PI+ON | 40 | 0.7±0.22 | 6 | 0.1±0.45 | ||
| NI+OP | 79 | 1.1±0.17 | 4 | 1.5±0.58 | ||
| 12 weeks | PI+OP | 28 | 0.7±0.32 | 2 | 0.0±1.49 | Main group effect F2, 143 =0.013; P=0.987 Main endpoint effect F1, 143 =1.032; P=0.312 group*endpoint interaction F2, 143 =0.009; P=0.990 |
| PI+ON | 32 | 0.7±0.30 | 8 | 0.2±0.61 | ||
| NI+OP | 76 | 0.7±0.21 | 3 | 0.0±1.05 | ||
| Beck Depression | ||||||
| 2 weeks | PI+OP | 64 | 19.5±1.07 | 38 | 23.0±1.39 | Main group effect F2, 300=0.199; P=0.819 Main endpoint effect F1, 300=3.464; P=0.064 group*endpoint interaction F2, 300=0.066; P=0.07 |
| PI+ON | 79 | 19.3±0.96 | 23 | 21.9±1.79 | ||
| NI+OP | 97 | 18.6±0.87 | 5 | 21.4±3.83 | ||
| 4 weeks | PI+OP | 50 | 10.5±1.27 | 14 | 14.3±2.60 | Main group effect F2, 234=0.353; P=0.703 Main endpoint effect F1, 234=0.152; P=0.697 group*endpoint interaction F2, 234=1.523; P=0.220 |
| PI+ON | 65 | 12.2±1.10 | 14 | 9.0±2.87 | ||
| NI+OP | 96 | 13.3±0.92 | 1 | 9.0±8.62 | ||
| 8 weeks | PI+OP | 30 | 7.3±1.45 | 2 | 6.0±3.48 | Main group effect F2, 155=0.801; P=0.450 Main endpoint effect F1, 155=0.059; P=0.809 group*endpoint interaction F2, 155=0.762; P=0.469 |
| PI+ON | 40 | 8.7±1.22 | 6 | 6.0±2.46 | ||
| NI+OP | 79 | 8.3±0.91 | 4 | 10.8±3.18 | ||
| 12 weeks | PI+OP | 28 | 4.7±1.55 | 2 | 21.0±7.10 | Main group effect F2, 143=1.028; P=0.361 Main endpoint effect F1, 143=4.577; P=0.035 group*endpoint interaction F2, 143=2.014; P=0.139 |
| PI+ON | 32 | 7.2±1.42 | 8 | 7.5±2.90 | ||
| NI+OP | 76 | 5.4±1.00 | 3 | 9.0±5.02 | ||
| Spielberger State Anxiety | ||||||
| 2 weeks | PI+OP | 64 | 47.6±1.24 | 38 | 50.2±1.61 | Main group effect F2, 300=0.264; P=0.768 Main endpoint effect F1, 300=5.906; P=0.016 group*endpoint interaction F2, 300=0.433; P=0.649 |
| PI+ON | 79 | 46.2±1.12 | 23 | 49.8±2.07 | ||
| NI+OP | 97 | 46.0±1.01 | 5 | 53.2±4.44 | ||
| 4 weeks | PI+OP | 50 | 41.2±1.73 | 14 | 45.6±3.54 | Main group effect F2, 234=2.182; P=0.115 Main endpoint effect F1, 234=2.699; P=0.102 group*endpoint interaction F2, 234=2.390; P=0.094 |
| PI+ON | 65 | 42.6±1.51 | 14 | 38.9±3.92 | ||
| NI+OP | 96 | 43.1±1.25 | 1 | 64.0±11.76 | ||
| 8 weeks | PI+OP | 30 | 38.7±2.32 | 2 | 38.2±5.58 | Main group effect F2, 155=1.070; P=0.345 Main endpoint effect F1, 155=0.004; P=0.951 group*endpoint interaction F2, 155=0.378; P=0.686 |
| PI+ON | 40 | 39.8±1.95 | 6 | 36.8±3.94 | ||
| NI+OP | 79 | 41.5±1.46 | 4 | 44.5±5.09 | ||
| 12 weeks | PI+OP | 28 | 37.0±2.39 | 2 | 42.0±10.96 | Main group effect F2, 143=0.057; P=0.945 Main endpoint effect F1, 143=0.292; P=0.590 group*endpoint interaction F2, 143=0.586; P=0.559 |
| PI+ON | 32 | 43.1±2.24 | 8 | 40.0±4.47 | ||
| NI+OP | 76 | 37.9±1.55 | 3 | 44.0±7.75 | ||
| Spielberger Trait Anxiety | ||||||
| 2 weeks | PI+OP | 64 | 47.3±1.16 | 38 | 50.5±1.51 | Main group effect F2, 300=0.092; P=0.912 Main endpoint effect F1, 300=4.694; P=0.031 group*endpoint interaction F2, 300=0.037; P=0.963 |
| PI+ON | 79 | 47.3±1.04 | 23 | 51.3±1.94 | ||
| NI+OP | 97 | 47.8±0.94 | 5 | 51.8±4.15 | ||
| 4 weeks | PI+OP | 50 | 42.9±1.49 | 14 | 44.2±3.04 | Main group effect F2, 234=0.189; P=0.828 Main endpoint effect F1, 234=0.340; P=0.560 group*endpoint interaction F2, 234=0.424; P=0.655 |
| PI+ON | 65 | 43.0±1.29 | 14 | 43.7±3.36 | ||
| NI+OP | 96 | 44.5±1.08 | 1 | 36.0±10.08 | ||
| 8 weeks | PI+OP | 30 | 40.4±1.90 | 2 | 41.6±4.57 | Main group effect F2, 155=1.548; P=0.216 Main endpoint effect F1, 155=0.003; P=0.960 group*endpoint interaction F2, 155=1.228; P=0.296 |
| PI+ON | 40 | 41.5±1.60 | 6 | 36.5±3.23 | ||
| NI+OP | 79 | 42.2±1.20 | 4 | 45.7±4.17 | ||
| 12 weeks | PI+OP | 28 | 39.9±2.22 | 2 | 59.0±10.16 | Main group effect F2, 143=1.508; P=0.226 Main endpoint effect F1, 143=1.498; P=0.224 group*endpoint interaction F2, 143=1.825; P=0.167 |
| PI+ON | 32 | 41.3±2.07 | 8 | 38.7±4.15 | ||
| NI+OP | 76 | 39.4±1.44 | 3 | 39.5±7.18 | ||
| Ferguson Anhedonia (Lack of Pleasure) | ||||||
| 2 weeks | PI+OP | 64 | 1.4±0.14 | 38 | 1.4±0.18 | Main group effect F2, 300=1.262; P=0.284 Main endpoint effect F1, 300=0.005; P=0.944 group*endpoint interaction F2, 300=0.555; P=0.575 Main endpoint effect (Mann-Whitney U) P=0.931 |
| PI+ON | 79 | 1.3±0.12 | 23 | 1.0±0.23 | ||
| NI+OP | 97 | 1.1±0.11 | 5 | 1.4±0.48 | ||
| 4 weeks | PI+OP | 50 | 0.5±0.17 | 14 | 0.9±0.34 | Main group effect F2, 234=0.204; P=0.816 Main endpoint effect F1, 234=0.548; P=0.460 group*endpoint interaction F2, 234=1.429; P=0.242 Main endpoint effect (Mann-Whitney U) P=0.858 |
| PI+ON | 65 | 0.8±0.15 | 14 | 0.3±0.38 | ||
| NI+OP | 96 | 0.9±0.12 | 1 | 0.0±1.14 | ||
| 8 weeks | PI+OP | 30 | 0.3±0.16 | 2 | 0.6±0.38 | Main group effect F2, 155=2.292; P=0.104 Main endpoint effect F1, 155=0.931; P=0.336 group*endpoint interaction F2, 155=2.207; P=0.113 Main endpoint effect (Mann-Whitney U) P=0.812 |
| PI+ON | 40 | 0.5±0.13 | 6 | 0.2±0.27 | ||
| NI+OP | 79 | 0.5±0.10 | 4 | 1.2±0.35 | ||
| 12 weeks | PI+OP | 28 | 0.3±0.12 | 2 | 1.0±0.54 | Main group effect F2, 143=2.270; P=0.109 Main endpoint effect F1, 143=1.457; P=0.230 group*endpoint interaction F2, 143=0.887; P=0.415 Main endpoint effect (Mann-Whitney U) P=0.070 |
| PI+ON | 32 | 0.4±0.11 | 8 | 0.7±0.22 | ||
| NI+OP | 76 | 0.1±0.08 | 3 | 0.0±0.39 | ||
| Ferguson Anhedonia (Lack of Interest) | ||||||
| 2 weeks | PI+OP | 64 | 1.2±0.13 | 38 | 1.2±0.17 | Main group effect F2, 300=0.237; P=0.789 Main endpoint effect F1, 300=0.055; P=0.944 group*endpoint interaction F2, 300=0.173; P=0.842 Main endpoint effect (Mann-Whitney U) P=0.792 |
| PI+ON | 79 | 1.1±0.12 | 23 | 1.0±0.22 | ||
| NI+OP | 97 | 1.0±0.11 | 5 | 1.2±0.47 | ||
| 4 weeks | PI+OP | 50 | 0.6±0.16 | 14 | 0.8±0.32 | Main group effect F2, 234=0.286; P=0.752 Main endpoint effect F1, 234=0.969; P=0.326 group*endpoint interaction F2, 234=1.468; P=0.233 Main endpoint effect (Mann-Whitney U) P=0.272 |
| PI+ON | 65 | 0.8±0.14 | 14 | 0.2±0.36 | ||
| NI+OP | 96 | 0.9±0.11 | 1 | 0.0±1.07 | ||
| 8 weeks | PI+OP | 30 | 0.2±0.15 | 2 | 0.6±0.37 | Main group effect F2, 155=1.504; P=0.225 Main endpoint effect F1, 155=2.123; P=0.147 group*endpoint interaction F2, 155=1.797; P=0.169 Main endpoint effect (Mann-Whitney U) P=0.502 |
| PI+ON | 40 | 0.6±0.13 | 6 | 0.4±0.26 | ||
| NI+OP | 79 | 0.5±0.10 | 4 | 1.2±0.34 | ||
| 12 weeks | PI+OP | 28 | 0.2±0.14 | 2 | 1.0±0.60 | Main group effect F2, 143=1.954; P=0.147 Main endpoint effect F1, 143=1.775; P=0.186 group*endpoint interaction F2, 143=1.161; P=0.317 Main endpoint effect (Mann-Whitney U) P=0.070 |
| PI+ON | 32 | 0.4±0.12 | 8 | 0.8±0.25 | ||
| NI+OP | 76 | 0.2±0.09 | 3 | 0.0±0.43 | ||
±